Cite
MLA Citation
M E Robson et al.. “OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.” Annals of oncology, vol. 30, 2019, pp. 558–566. http://access.bl.uk/ark:/81055/vdc_100094073912.0x000039